EGFR and non-small cell lung carcinoma: These results are in accordance with recent studies, which reported that among 231 patients with EGFR mutant stage IV NSCLC, mPFS and mOS were significantly longer for the local consolidation therapy (surgery or radiotherapy) plus TKIs group than the TKIs monotherapy group (23).